Key takeaways
- A consolidated multi-district lawsuit involving more than 130 cases alleges that GLP-1 drugs cause an irreversible eye stroke condition known as NAION.
- A Boston Mass Eye and Ear study found diabetic GLP-1 users were four times more likely, and overweight users seven times more likely, to be diagnosed with NAION.
- While European and UK labels warn of this rare vision risk, U.S. packaging does not currently feature the same warnings.
- The CDC recommends that patients taking GLP-1 medications visit an ophthalmologist to establish a baseline vision examination.
What happened
A multi-district lawsuit consolidating more than 130 cases is underway before a federal judge in Philadelphia, targeting prominent pharmaceutical manufacturers Novo Nordisk and Eli Lilly. The litigation alleges that popular GLP-1 receptor agonists—including Wegovy, Ozempic, Mounjaro, and Zepbound—can cause non-arteritic anterior ischemic optic neuropathy (NAION), a rare and irreversible form of permanent vision loss often referred to as an "eye stroke."
Why it matters
For the millions of Americans utilizing online telehealth platforms or traditional clinics to secure GLP-1 prescriptions, understanding the distinction between sensationalized legal headlines and clinical risk is vital. NAION is an irreversible condition caused by restricted blood flow to the optic nerve. It occurs suddenly and without warning, typically causing patients to wake up with permanent vision loss in one or both eyes.
While the litigation is in its early stages and could take years to resolve, the legal push has intensified discussions surrounding drug warning labels. Currently, regulators in Europe and the United Kingdom have updated safety labels for semaglutide to warn of this rare condition. However, U.S. packaging does not feature the same prominent warnings, leaving many domestic buyers unaware of the potential connection. If the lawsuits succeed, they could force U.S. regulators to mandate stricter warning labels, changing how telehealth providers screen patients and discuss potential GLP-1 side effects.
What the data says
The legal battle hinges on contrasting clinical studies and corporate data regarding the statistical likelihood of developing NAION:
- The Mass Eye and Ear Study (2024): Published in JAMA Ophthalmology by researchers at Mass Eye and Ear in Boston, this study analyzed patient registries to evaluate the correlation. It revealed that diabetic patients prescribed GLP-1 medications were more than four times more likely to be diagnosed with NAION compared to those on other treatments. Furthermore, overweight or obese patients taking GLP-1s were more than seven times more likely to receive a NAION diagnosis.
- The Manufacturer Defense: Eli Lilly maintains that patient safety is its top priority, noting that recent medical literature has concluded "evidence does not establish a causal relationship between GLP-1RAs and NAION." Novo Nordisk conducted its own internal study analyzing 96,000 patients and reported finding no increased risk of the condition.
- Patient Experiences: Plaintiffs in the multi-district lawsuit describe sudden, life-altering vision loss. Diane Wirth, a former nurse practitioner who took Wegovy in early 2025, woke up weeks later permanently blind in her right eye, which ultimately forced her to leave her career. Another plaintiff, a 48-year-old man from New York, lost sight in both eyes.
In light of these findings, the Centers for Disease Control and Prevention (CDC) has issued a statement recommending that patients taking GLP-1 medications consult an ophthalmologist to establish a baseline vision examination.
How it compares
When shopping for weight-loss treatments, patients must weigh these rare, severe ophthalmic risks against better-known side effects and the benefits of different drug families.
Semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Zepbound and Mounjaro) have both been named in the litigation. While the JAMA Ophthalmology study specifically highlighted semaglutide, both drug classes are under scrutiny.
For cash-paying consumers, the decision-making process often involves comparing brand-name drugs to compounded alternatives. Brand-name Wegovy and Zepbound carry list prices ranging from $1,000 to nearly $1,350 per month, though online telehealth providers often connect patients to compounded semaglutide or tirzepatide for $200 to $400 per month. Regardless of whether a patient chooses brand-name or compounded options, the underlying active peptides carry the same biological risks. Consequently, patients utilizing cheapest telehealth GLP-1 services should ensure their virtual provider performs a comprehensive health screening before prescribing.
How this fits the bigger picture
This litigation represents a growing wave of legal and regulatory scrutiny targeting the safety profiles of blockbuster weight-loss drugs. Over the past year, the rapid expansion of the GLP-1 market has forced regulators and health systems to balance unprecedented demand with emerging safety signals.
This is not the first time international and domestic safety reports have clashed. In our coverage of how Australia reports 62 deaths linked to GLP-1 drugs, we highlighted how global regulators analyze adverse event databases, emphasizing that association does not automatically equal causation. Similarly, as the market expands, unexpected side effects continue to emerge. We recently reported on how a dentist warns GLP-1s cause dry mouth, which can accelerate tooth decay. These developments show that as millions of new users adopt these medications, the clinical understanding of their full systemic effects is still evolving.
For U.S. buyers, the lack of unified global labeling means they must act as their own advocates. While European regulators have already updated semaglutide labels to reflect NAION risks, U.S. buyers rely on telehealth platforms or primary care doctors to communicate these developments.
What happens next
The multi-district litigation before the Philadelphia federal judge is expected to proceed slowly, potentially taking years to reach a trial or settlement. In the meantime, the FDA will continue to monitor adverse event reporting databases to determine if a formal U.S. label change is warranted for Wegovy, Ozempic, Mounjaro, and Zepbound.
Patients currently taking or considering a GLP-1 medication should discuss their personal risk factors for NAION—such as high blood pressure, sleep apnea, or a pre-existing optical condition—with their doctor. Following the CDC's guidance, scheduling a baseline eye exam with an ophthalmologist is a prudent step for anyone starting these therapies.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication regimen.